52 results about "Pathogenic Escherichia coli" patented technology

The present disclosure provides compositions and methods for making and using Salmonella recombinant bacteria that express LPS O78 antigen and / or virulence factors of avian pathogenic Escherichia coli (APEC) as vaccines to prevent colibacillosis infections.

The invention discloses a high-strength nano-composite antibacterial fabric which comprises a base fabric and a modified and sol-gel nano layer, the modified and sol-gel nano layer and the base fabric are compounded and smeared to form the nano-composite antibacterial fabric, and the modified and sol-gel nano layer is coated with the modified and sol-gel nano layer to form the high-strength nano-composite antibacterial fabric. The modified sol-gel nano layer comprises titanium dioxide sol, nano zinc oxide and a silver antibacterial agent, the base layer fabric is prepared from the following raw materials in percentage by weight: 10% of chitin fiber, 50% of Coolplus fiber, 40% of cotton fiber and 16.7 tex of yarn linear density, and the base layer fabric is prepared from the following raw materials in percentage by weight: 10% of chitosan fiber, 50% of Coolplus fiber, 40% of cotton fiber and 16.7 tex of yarn linear density. Compared with the prior art, the fabric has the advantages that a layer of uniform and firm porous nano antibacterial film is formed on the surface of the fabric, so that staphylococcus aureus and pathogenic escherichia coli can be effectively killed; the double-layer fabric formed by combining the chitin fibers, the Coolplus fibers and the cotton fibers has good antibacterial, bacteriostatic, rapid moisture absorption and moisture conduction functions.

A method for preparing a bacteriophage targeting extra-intestinal pathogenic Escherichia coli (ExPEC) comprising mixing pig (porcine) extraintestinal E. coli host cells at logarithmic phase with phage

The invention provides a product for detecting eight food-borne pathogenic bacteria by time-of-flight mass spectrometry, which comprises a specific primer group of multiple PCR (Polymerase Chain Reaction) of the eight food-borne pathogenic bacteria, wherein the food-borne pathogenic bacteria comprise intestinal aggregation Escherichia coli, intestinal hemorrhagic Escherichia coli, intestinal invasive Escherichia coli, intestinal pathogenic Escherichia coli, Shiga toxin producing Escherichia coli, enterotoxin producing Escherichia coli, listeria monocytogenes and salmonella typhimurium. The detection vehicle product is used for carrying out multiple PCR amplification on pathogen DNA, and the size of a fragment of the multiple PCR product is detected through MALDI-TOF MS (matrix-assisted laser desorption / ionization time of flight mass spectrometry). According to the method, multiple PCR and MALDI-TOF MS are combined to be used for identifying clinical pathogenic microorganisms, and the method is rapid, simple, convenient, easy to observe, visual and high in accuracy.

The invention discloses a traditional Chinese medicine composition for preventing and treating avian pathogenic escherichia coli as well as a preparation method and application thereof, and relates to the technical field of veterinary drugs. According to the invention, screening is carried out through subtraction genomics and reverse network pharmacology, and based on the compatibility theory of monarch, minister, assistant and guide and the traditional Chinese veterinary medicine and pharmacy differentiation theory, a traditional Chinese medicine composition, namely the radix angelicae and fructus forsythiae intestine health formula, for preventing and treating avian pathogenic escherichia coli is formed. According to the traditional Chinese medicine composition, fructus forsythiae and radix angelicae are used as monarch drugs, radix isatidis and clinopodium polycephalum are used as ministerial drugs, fructus aurantii immaturus, mint and plantain herb are used as adjuvant drugs, and liquorice is used as a conductant drug, so that the traditional Chinese medicine composition can inhibit reproduction of avian pathogenic escherichia coli, destroy formation of biological membranes of the avian pathogenic escherichia coli and relieve pathological injuries of diseased poultry caused by APEC; the traditional Chinese medicine composition has a good treatment effect on avian pathogenic escherichia coli.

The invention relates to the technical field of microorganisms, in particular to an escherichia coli bacteriophage for improving the antibacterial effect of cecropin and application of the escherichia coli bacteriophage. The bacteriophage is named as RDP-EC-22139, the genome of the bacteriophage does not contain virulence genes and lyogenicity related genes, and the bacteriophage has good biological safety. The bacteriophage has relatively strong lysis activity on drug-resistant pathogenic escherichia coli, can still keep stable lysis titer in a relatively wide temperature and pH condition range, and has good genetic stability. When the bacteriophage is combined with cecropin for use, the minimum inhibitory concentration of the cecropin on drug-resistant pathogenic escherichia coli is remarkably reduced, the minimum inhibitory concentration can be reduced to 1 / 2-1 / 8 of the minimum inhibitory concentration when the cecropin is independently used, the inhibition time on pathogenic bacteria is remarkably prolonged, and a stable and unexpected synergistic antibacterial effect is shown. The invention provides a safe and effective biological technical scheme for prevention and control of drug-resistant Escherichia coli infection, and has a good application prospect.

The invention discloses a bacteriophage capable of splitting pathogenic escherichia coli and application of the bacteriophage. The phage is named as Escherichia coli phage vBEcoMYS1, and is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number of the phage is GDMCC No: 67465-B1vBEcoMYS1. Experiments prove that the bacteriophage has relatively strong splitting capacity, relatively strong thermal stability and relatively strong pH stability, and can keep high titer under the conditions that the temperature is 4-40 DEG C and the pH is 5-9. The bacteriophage can be used for splitting multiple escherichia coli, including enterotoxigenic escherichia coli (ETEC) and shiga toxin-producing escherichia coli (STEC), has a relatively wide splitting spectrum, and can be used as an antibiotic substitute. In addition, the genome of the bacteriophage does not contain virulence genes and antibiotic resistance genes, so that the bacteriophage has good biological safety.

The invention relates to the technical field of molecular biomedicine, in particular to a method for identifying enteropathogenic Escherichia coli, which comprises the following steps: screening virulence genes, determining a Cutom Markers gene, detecting mNGS of a clinical specimen, comparing off-machine data and identifying the enteropathogenic Escherichia coli. The specificity of the identification method reaches 99.9%, and the sensitivity reaches 96.8% when the detection sequence of escherichia coli is greater than or equal to 10k reads. By utilizing the method, the accuracy and applicability of enteropathogenic escherichia coli identification can be remarkably improved, and the method can be widely applied to the field of clinical microbiological detection.

The application belongs to the technical field of bioengineering, and particularly relates to a bacteriophage PE-2 of Escherichia coli with high blood entry efficiency and fermentation efficiency and application. The bacteriophage involved in the application has a preservation number of CCTCC NO: M20252973, and can specifically lyse pathogenic Escherichia coli O2 serotype and has high blood entry efficiency. The bacteriophage can enter blood circulation through oral administration, and can be widely distributed to the spleen, liver, heart and other tissues through blood circulation. The bacteriophage can be prepared in pilot production to obtain a very high titer, and the titer reaches 1.6x10 12 PFU / mL. Compared with the production of antibiotics, the production cost of the bacteriophage is low, and the bacteriophage provides a source and a reference example for industrial production of high-titer bacteriophage.

The invention provides a kit for detecting multiple piglet diarrhea pathogens and a detection method, and belongs to the technical field of biological information detection. The kit comprises a reaction reagent, wherein the reaction reagent comprises a porcine epidemic diarrhea virus specific primer and a probe, a porcine delta coronavirus specific primer and a probe, a piglet pathogenic escherichia coli specific primer and a probe, a clostridium perfringens specific primer and a probe, a buffer solution, an enzyme mixed solution and a freeze-drying protective additive. The detection method adopts the kit for detecting various piglet diarrhea pathogens. According to the kit disclosed by the invention, simultaneous detection of four target genes including the porcine epidemic diarrhea virus, the porcine delta coronavirus, the piglet pathogenic escherichia coli and the clostridium perfringens can be realized only through one-time amplification, so that the detection time is greatly shortened while the detection cost is reduced; the kit has extremely high specificity, sensitivity and repeatability, and the primers and the probes do not interfere with each other; good normal-temperature storage stability is also realized.

The invention discloses a strain of leuconostoc mesenteroides V7, and the microbial preservation number is CGMCC (China General Microbiological Culture Collection Center) No.34824. The leuconostoc mesenteroides V7 disclosed by the invention is applied to products for inhibiting source avian pathogenic escherichia coli. The leuconostoc mesenteroides V7 disclosed by the invention has an inhibition effect on avian pathogenic escherichia coli, so that the leuconostoc mesenteroides V7 can be used for replacing antibiotics in poultry production and breeding to treat avian pathogenic colibacillosis. The invention provides a novel antibiotic substitute, which can obviously improve the infection condition of avian pathogenic escherichia coli in poultry bodies and avoid the problems of antibiotic abuse and bacterial drug resistance as much as possible.

The application discloses a dog-derived Enterococcus faecalis ZJUIDS-D016 with anti-aging effect and application, the dog-derived Enterococcus faecalis ZJUIDS-D016 is classified and named as (Enterococcus faecalis) Enterococcus faecalis ), and the preservation number is CGMCC 27038.The strain of the application is isolated from the intestinal tract of a healthy dog, has acid resistance, bile salt resistance and broad-spectrum antibacterial activity, and is sensitive to chloramphenicol, erythromycin and penicillin.The strain of the application has strong host adaptability, can colonize in the intestinal tract of a dog and secrete organic acids and bacteriocins, significantly inhibits the proliferation of common pathogenic bacteria such as dog pathogenic escherichia coli, effectively improves the intestinal health of pets and delays aging, and is suitable for preparing pet probiotic products.

The invention relates to the technical field of escherichia coli biofilm formation determination, in particular to a method for determining the escherichia coli biofilm formation capacity through a crystal violet staining method. The method comprises the steps of bacterial liquid preparation, microwell plate sterilization, inoculation and culture, washing and fixation, dyeing and dissolution and quantitative detection. The method comprises the following steps: systematically analyzing biological characteristics such as biofilm forming ability, drug resistance, drug resistance genes and virulence genes of avian pathogenic escherichia coli through a multi-dimensional evaluation system, introducing a local isolated strain in Gansu province as a contrast, screening a strong biofilm forming strain in combination with ANOVA, and detecting the virulence genes through PCR (Polymerase Chain Reaction). The invention finds that the drug resistance rate of beta-lactams in a strong biofilm strain is as high as 82.3%, target data is provided for regional antibiotic control, meanwhile, a biofilm strength-virulence gene-drug resistance spectrum correlation model is established, the limitation of single phenotypic research is broken through, and the clinical treatment guidance value is improved.

The application discloses a protein molecule and application thereof in identifying avian pathogenic Escherichia coli of multiple serotypes, relates to the biological field, and the amino acid sequence of the protein molecule is shown as SEQ ID No:1. The protein molecule can specifically recognize avian pathogenic Escherichia coli of O2, O18 and O78 antigen serotypes, can be used for identifying avian pathogenic Escherichia coli of O2, O18 and O78 antigen serotypes, has the advantages of simplicity, rapidness, accuracy and the like, and has high application value.

The invention discloses a bacterial infection and LPS induced broiler chicken liver injury model and a construction method and application thereof, and the construction method comprises the following steps: administering 10-day-old broiler chicken with Escherichia coli E.coli O78 with a preset concentration in an intragastric administration manner; after broiler chickens are subjected to intragastric administration of escherichia coli for 18 hours, an LPS solution is injected into the intraperitoneal cavity of the broiler chickens, after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained, when the broiler chickens are 11 days old, the broiler chickens subjected to intragastric administration of escherichia coli are subjected to intraperitoneal injection of the LPS solution, and after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained. The broiler chicken liver injury model is constructed by intragastric administration of avian pathogenic escherichia coli (E.coli O78) and intraperitoneal injection of LPS (2 mg / kg), the pathology of the model is highly consistent with that of clinical broiler chicken bacterial liver injury, the liver has clinical typical lesions macroscopically, liver cells are degenerative and necrotic microscopically, and a molecular pathway activation mode is consistent with that of clinical application; the model constructed by the invention realizes specific liver injury, only the liver has specific injury, multiple organ lesions such as heart, peritoneum and the like do not exist, and the model availability is high.

The present disclosure relates to a composition for use in reducing the risk of an infection of the gastrointestinal tract caused by a pathogenic E. coli in a human subject, said composition comprising an effective amount of 2´-fucosyllactose, 3-fucosyllactose, 3'-sialyllactose, 6´-sialyllactose, and lacto-N-tetraose.

Method for detecting pathogenic strains of Escherichia coli expressing the f17g gene of the F17 fimbria gene. The invention relates to a detection method based on the amplification of the genomic DNA of the pathogenic strain using LAMP technology with specific primers at a temperature of 62°C. This reaction is carried out with the Cas12a enzyme, previously activated with a guide RNA specific to the F17g gene. This method allows for the rapid detection of pathogenic strains with rudimentary equipment and can be associated with a rapid diagnostic device in the field.

The invention discloses application of luteoloside in preparation of a medicine for inhibiting adhesion and invasion of uropathogenic escherichia coli, and belongs to the technical field of medical biology. The technical problem to be solved is to provide new application of the luteoloside, and research finds that although the luteoloside does not have a direct bacteriostatic effect, the luteoloside significantly inhibits UPEC movement and biofilm formation, destroys a pilus / flagellum ultrastructure, and down-regulates virulence genes (fimH, papG and fliC). The luteoloside can reduce UPEC adhesion and invasion, restore the barrier function and reduce the level of IL-6 and TNF-alpha. Therefore, the luteoloside is used as a host-oriented antivirulence natural product, the pathogenic effect of the luteoloside is effectively relieved by inhibiting UPEC virulence and regulating CAV1 related epithelial process, and transformation application potential is provided for management of urinary tract infection.

The application discloses application of deacetylase inhibitor LMK235 in preparation of a medicine for treating chronic urinary tract infection and a medicine preparation thereof, and belongs to the field of biological medicines. The chronic urinary tract infection is induced by uropathogenic Escherichia coli. Experiments show that LMK235 can effectively reduce the amount of bacteria in urine and the amount of bacteria in the bladder by significantly reducing the colonization of uropathogenic Escherichia coli in the bladder in mice; and the chronic inflammation of the bladder caused by uropathogenic Escherichia coli infection can be improved by significantly reducing the level of inflammatory cytokine IL-1b in the bladder. The application widens the application field of the deacetylase inhibitor LMK235, provides an experimental basis for clinical application of LMK235 in preparation of a medicine for treating urinary system infection, and has a good application prospect, great potential value and social significance.

The present invention relates to probiotic bacteria of the species E. coli, in particular in combination with bacteria of the species Klebsiella oxytoca, that are used for a decolonization of pathogenic and / or multidrug resistant (MDR) Enterobacteria, such as pathogenic E. coli and / or Klebsiella pneumoniae (K. pneumoniae), Enterococci and / or Acinetobacter, from the gut of a subject. The decolonization can both be therapeutic, i.e. after colonization of the gut by the pathogenic and / or multi-resistant pathogen(s), or as a preventive measure before a re-colonization of the gut, as required after antibiotic treatment or treatment-induced dysbiosis.

The application discloses a Salmonella phage nct1, and the Salmonella phage nct1 (Salmonella phage nct1) has a preservation number of CCTCC NO: M 20221037. The Salmonella phage nct1 has small toxic and side effects, high safety, a relatively wide temperature and acid-base tolerance range, and good killing and prevention and control effects on environments, foods and the like contaminated by Salmonella and pathogenic Escherichia coli.

The invention discloses an epidemic disease prevention, detection and purification method for Sansui duck breeding, which is used for daily epidemic disease prevention and control of commercial duck farms and breeding duck farms of Sansui ducks, and comprises the following steps: S1, epidemic disease detection and screening aiming at duck tembusu virus disease, riemerella anatipestifer disease and duck poultry pathogenic colibacillosis; s2, obtaining a detection result in the step S1 for isolation; s3, breeding monitoring and activity track analysis are checked for infection prevention; s4, disinfecting the functional area during a non-epidemic period, collecting an environmental swab, and laying an infection prevention area; s5, after the S3 and the S4 are executed, the S1 is executed regularly, and continuous monitoring implementation is carried out for more than six months; and S6, when the positive individuals appear in the S5, repeating the steps S3-S5 until no positive individuals exist in the continuous monitoring period. Compared with the prior art, the epidemic disease prevention, detection and purification method for Sansui duck breeding has the advantages of being good in purification, prevention and control effect and capable of synchronously aiming at DTMUV, RA and APEC epidemic diseases.

The invention discloses a B cell conservative epitope peptide of enterotoxigenic Escherichia coli V-type secretion system effect protein EatA and application thereof, and particularly relates to application in ETEC specific antibody diagnosis. The B cell conservative epitope peptide disclosed by the invention can be functionally displayed and expressed on the surface of an inert carrier S9H thallus, PT8 is displayed and expressed on the surface of the S9H thallus, and an agglutination test directly mediated by the PT8 and specifically recognized by an antibody is established, so that only ETEC pathogen infectious antibodies are specifically recognized, other pathogenic escherichia coli can be identified and diagnosed, and the B cell conservative epitope peptide has a good application prospect. And no cross reaction with serum antibodies of other infectious diseases exists. According to the method, the specific serum antibody can be detected 7 days after a Balb / c mouse is infected by the ETEC strain H10407. The diagnosis method is high in specificity, good in sensitivity, convenient to operate and intuitive in result judgment, and is expected to become a technical means for visual on-site accurate and convenient diagnosis of ETEC infection.

The invention discloses an escherichia coli bacteriophage GXEC2-19, which is an escherichia coli bacteriophage GXEC2-19, the preservation number of the escherichia coli bacteriophage GXEC2-19 is CCTCC (China Center for Type Culture Collection) NO: M 20242555, and the preservation number of the escherichia coli bacteriophage GXEC2-19 is CCTCC NO: M 20242555. The invention also discloses an application of the coliphage GXEC2-19 in preparation of drugs for preventing and treating avian pathogenic coliphage infection diseases. The escherichia coli phage GXEC2-19 Escherichia phage GXEC2-19 disclosed by the invention can be used for effectively cracking chicken-origin pathogenic escherichia coli, wherein the chicken-origin pathogenic escherichia coli comprises escherichia coli phage DC05 and another strain of chicken-origin escherichia coli; furthermore, the coliphage GXEC2-19 can continuously inhibit bacteria for a long time, is high in stability and good in safety, can be easily prepared into preparations and the like, and has good killing, preventing and controlling effects on environments, feeds and the like polluted by the coliphage.

The present disclosure provides compositions and methods for making and using Salmonella recombinant bacteria that express LPS O78 antigen and / or virulence factors of avian pathogenic Escherichia coli (APEC) as vaccines to prevent colibacillosis infections.

The purpose of the present invention is to provide a method for producing an animal model infected with Enterobacteriaceae bacteria such as pathogenic Escherichia coli. Provided is a method for producing an animal model infected with Enterobacteriaceae bacteria, the method comprising step (1) and step (2) in the following order. (1) A step for administering a β-lactam antibacterial agent to a non-human mammal; (2) a step including the following steps (2-1) and (2-2) in random order; (2-1) a step for administering at least one selected from the group consisting of lincomycin antibacterial agents and macrolide antibacterial agents to the non-human mammal; and (2-2) a step for administering Enterobacteriaceae bacteria to the non-human mammal

The invention provides a protein molecule and application thereof in identifying avian pathogenic escherichia coli with various serotypes, and relates to the field of biology, and the amino acid sequence of the protein molecule is shown as SEQ ID No: 1. The protein molecule can specifically recognize the avian pathogenic escherichia coli of the O2, O18 and O78 antigen serotypes, can be used for identifying the avian pathogenic escherichia coli of the O2, O18 and O78 antigen serotypes, has the advantages of simplicity, rapidness, accuracy and the like, and is high in application value.

The present invention discloses an anti-S11 Riemerella anatipestifer monoclonal antibody and a blocking ELISA antibody detection kit and application thereof, belonging to the technical field of avian immunology. The monoclonal antibody provided by the present invention comprises a heavy chain and a light chain, wherein the heavy chain comprises VHCDR1, VHCDR2 and VHCDR3 as shown in the amino acid sequence of SEQ ID NO:1-3, and the light chain comprises VLCDR1 as shown in the amino acid sequence of SEQ ID NO:4, VLCDR2 with the amino acid sequence of LVS and VLCDR3 as shown in the amino acid sequence of SEQ ID NO:5; the blocking ELISA antibody detection kit prepared from the monoclonal antibody can specifically detect the level of antibodies to Riemerella anatipestifer serotype 11 (S11 type) in a sample, and has no cross-reactivity with Riemerella anatipestifer S1, S2, S5, S6 and S14 types, avian pathogenic Escherichia coli, avian Pasteurella and Salmonella, with high sensitivity and strong specificity.

The invention discloses a drug-resistant Escherichia coli bacteriophage with efficient cross-species lysis capability and application of the drug-resistant Escherichia coli bacteriophage, the drug-resistant Escherichia coli bacteriophage is named as Escherichia coli bacteriophage PE-48, and the preservation number of the drug-resistant Escherichia coli bacteriophage is CCTCC (China Center for Type Culture Collection) NO: M 2025261. The strain not only can efficiently split pathogenic escherichia coli, but also can split salmonella, has efficient cross-species splitting capacity, and can effectively prevent and treat various symptoms caused by escherichia coli and relieve phenomena such as large-scale death and the like. The bacteriophage is separated from the natural environment, is a natural biological purification factor, and has the advantages of being green, environmentally friendly, safe, free of residues, efficient in bacteriostasis and the like. Escherichia coli and salmonella infection can be effectively prevented and treated in the chick breeding process.